Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A



Status:Withdrawn
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - 64
Updated:9/27/2018
Start Date:April 2005
End Date:November 2005

Use our guide to learn which trials are right for you!

A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)

The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate,
using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.


Inclusion Criteria:

- Severe hemophilia A

- Previously treated patients with at least 150 exposure days to any Factor VIII product

Exclusion Criteria:

- Hypersensitivity to any recombinant Factor VIII product

- History of or current Factor VIII inhibitor

- Bleeding episode or other reason requiring Factor VIII treatment within 3 days of
study
We found this trial at
5
sites
?
mi
from
Washington,
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Brussels,
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials